Cancer Invest

GLP-1 RAs tied to lower 5-year mortality in colon cancer

November 18, 2025

A retrospective analysis of 6,871 patients with primary colon cancer from the University of California Health Data Warehouse examined the association between GLP-1 RA use and five-year mortality. Mortality was 15.5% among GLP-1 RA users vs. 37.1% among nonusers. After adjustment for confounders, GLP-1 RA use was associated with significantly lower odds of death (odds ratio, 0.38; 95% confidence interval, 0.21–0.64). Stratified modeling indicated this benefit was limited to patients with BMI >35. Authors note the findings highlight a potential role for metabolic factors in colon cancer outcomes.

Source:

Cuomo, RE. (2025, November 11). Cancer Invest. The Influence of GLP-1 Receptor Agonists on Five-Year Mortality in Colon Cancer Patients. https://pubmed.ncbi.nlm.nih.gov/41216819/